Huangpu boosts biopharma growth through global partnerships

Recently in Shanghai, the Huangpu district 2023 life and health industry seminar was convened.

In collaboration with leading international consultancy OCO Global and the China Association of Enterprises with Foreign Investment, the event gathered representatives from 20 top foreign Global Fortune 500 companies and government agencies. 

The focus was on exploring investment opportunities for Huangpu in the Guangdong-Hong Kong-Macao Greater Bay Area, aiming to accelerate the growth of Guangzhou's biopharmaceutical industry.

The initiative saw the involvement of executives from the Global Fortune 500 companies, including Pfizer and Lonza, who came together with governmental representatives to discuss potential collaboration.

Answering the call of the State Council, China's Cabinet, Huangpu has actively sought out foreign investments. This has led to a significant surge in its biopharma industry, positioning it as a national frontrunner.

Several international corporations have praised the solid infrastructure and expansive market potential of the Greater Bay Area. What’s more, Huangpu is emerging as a hotspot for investments in the biopharma world.

The district's open-strategy approach has successfully attracted foreign capital, further enriching Guangzhou's standing in the biopharmaceutical landscape.